PRESTO: a phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19) 2024

Phase III randomized, placebo-controlled clinical trial of donepezil for treatment of cognitive impairment in breast cancer survivors after adjuvant chemotherapy (WF-97116) 2024

Effects of a geriatric assessment intervention on patient-reported symptomatic toxicity in older adults with advanced cancer 2023

A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45) 2022

Orteronel for metastatic hormone-sensitive prostate cancer: a multicenter, randomized, open-label phase III trial (SWOG-1216) 2022

Randomized phase II study of PET response-adapted combined modality therapy for esophageal cancer: mature results of the CALGB 80803 (Alliance) Trial 2021

Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131 2021

NSABP B-47/NRG Oncology Phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2 2020

Phase Ib/II clinical trial of pembrolizumab with bevacizumab for metastatic renal cell carcinoma: BTCRC-GU14-003 2020

Randomized trial of lenalidomide versus observation in smoldering multiple myeloma 2020

Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient 2020

Randomized phase II trial of cisplatin and etoposide in combination with veliparib or placebo for extensive-stage small-cell lung cancer: ECOG-ACRIN 2511 Study 2019

Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG Oncology/RTOG 0813 Trial 2019

Longitudinal trajectory and characterization of cancer-related cognitive impairment in a nationwide cohort study 2018

Randomized phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: results of PrE0102 2018

Randomized, multicenter, placebo-controlled clinical trial of duloxetine versus placebo for aromatase inhibitor-associated arthralgias in early-stage breast cancer: SWOG S1202 2018

Anthracyclines in early breast cancer: the ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology) 2017

E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx- ECOG-ACRIN Cancer Research Group 2017

Intentional weight loss and endometrial cancer risk 2017

Long-term follow-up of cardiac function and quality of life for patients in NSABP protocol B-31/NRG oncology: a randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel with AC followed by paclitaxel and trastuzumab in patients with node-positive breast cancer with tumors overexpressing human epidermal growth factor receptor 2 2017

Awareness of breast density and its impact on breast cancer detection and risk 2015

Diabetes, metformin, and breast cancer in postmenopausal women 2012

What a difference a letter can make 2012

Increasing rates of contralateral prophylactic mastectomy among patients with ductal carcinoma in situ 2009

Referral, receipt, and completion of chemotherapy in patients with early-stage breast cancer older than 65 years and at high risk of breast cancer recurrence 2009

Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer 2008

A randomized trial of topical cannabis balms for the treatment of aromatase inhibitor–associated musculoskeletal syndrome (AIMSS) [abstract] 2024

Cannabis use for cancer-related symptoms in rural versus urban Minnesota [abstract] 2024

Phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with Pembrolizumab: clinical update [abstract] 2024

A novel cannabis education clinic for patients with cancer: patient characteristics from initial visit [abstract] 2022

Self-reported efficacy and usage of cannabis among patients with cancer within the Minnesota Cannabis Program [abstract] 2022

Using machine learning to identify older adults at high risk for hospitalization and mortality via the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) [abstract] 2020

Tumor characteristics and treatment in early-onset colorectal cancer [abstract] 2018

Medical scribes in a community oncology clinic [abstract] 2016

A randomized trial of vitamin D3 in aromatase inhibitor-associated musculoskeletal symptoms [abstract] 2015

Association between musculoskeletal symptoms and serum vitamin D levels in women receiving aromatase inhibitor treatment [abstract] 2013

Validation of genomic markers that predict distant recurrence risk via FISH assays in women with early stage breast carcinoma [abstract] 2007